The US FDA has approved SELARSDI that Israel’s Teva has developed with Europe’s Alvotech. SELARSDI is a biosimilar (see here previously) to the costly branded Stelara. It treats adult and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn’s disease, and ulcerative colitis.

https://en.globes.co.il/en/article-teva-jumps-on-fda-approval-for-biosimilar-1001509454